Literature DB >> 11891942

FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.

Eva Brun1, Elisabeth Kjellén, Jan Tennvall, Tomas Ohlsson, Anders Sandell, Roland Perfekt, Roland Perfekt, Johan Wennerberg, Sven Erik Strand.   

Abstract

BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC.
METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years.
RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively.
CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891942     DOI: 10.1002/hed.10037

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  73 in total

1.  Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma.

Authors:  Masahiro Kikuchi; Yuji Nakamoto; Shogo Shinohara; Keizo Fujiwara; Hiroshi Yamazaki; Yuji Kanazawa; Risa Kurihara; Ippei Kishimoto; Hiroyuki Harada; Yasushi Naito
Journal:  Int J Clin Oncol       Date:  2012-03-09       Impact factor: 3.402

Review 2.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

3.  Predictive value of fluorodeoxyglucose uptake in head and neck cancer: importance of standardization: editorial on EAORL-D-10-00277.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-04       Impact factor: 2.503

4.  Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

Authors:  Hyung Jun Im; Tae Sung Kim; Seog-Yun Park; Hye Sook Min; June Hyuk Kim; Hyun Guy Kang; Seung Eun Park; Mi Mi Kwon; Jong Hyung Yoon; Hyeon Jin Park; Seok-ki Kim; Byung-Kiu Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-28       Impact factor: 9.236

Review 5.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

6.  Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma.

Authors:  Vincent Vandecaveye; Piet Dirix; Frederik De Keyzer; Katya Op de Beeck; Vincent Vander Poorten; I Roebben; Sandra Nuyts; Robert Hermans
Journal:  Eur Radiol       Date:  2010-02-24       Impact factor: 5.315

7.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.

Authors:  Nanda C Krak; R Boellaard; Otto S Hoekstra; Jos W R Twisk; Corneline J Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-15       Impact factor: 9.236

Review 8.  Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy.

Authors:  Markus Schwaiger; Christian Peschel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

9.  Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.

Authors:  Chia-Hung Kao; Shih-Chieh Lin; Te-Chun Hsieh; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Ji-An Liang; Chun-Hung Hua; Shang-Wen Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-25       Impact factor: 9.236

Review 10.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.